RT Journal Article SR Electronic T1 SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.27.21259271 DO 10.1101/2021.06.27.21259271 A1 Mohamed Bailor Barrie A1 Sulaiman Lakoh A1 J. Daniel Kelly A1 Joseph Sam Kanu A1 James Squire A1 Zikan Koroma A1 Silleh Bah A1 Osman Sankoh A1 Abdulai Brima A1 Rashid Ansumana A1 Sarah A. Goldberg A1 Smit Chitre A1 Chidinma Osuagwu A1 Justin Maeda A1 Bernard Barekye A1 Tamuno-Wari Numbere A1 Mohammed Abdulaziz A1 Anthony Mounts A1 Curtis Blanton A1 Tushar Singh A1 Mohamed Samai A1 Mohamed A. Vandi A1 Eugene T. Richardson YR 2021 UL http://medrxiv.org/content/early/2021/07/05/2021.06.27.21259271.abstract AB Background As of 26 March 2021, the Africa CDC had reported 4,159,055 cases of COVID-19 and 111,357 deaths among the 55 African Union Member States; however, no country has published a nationally representative serosurvey as of May 2021. Such data are vital for understanding the pandemic’s progression on the continent, evaluating containment measures, and policy planning.Methods We conducted a cross-sectional, nationally representative, age-stratified serosurvey in Sierra Leone in March 2021 by randomly selecting 120 Enumeration Areas throughout the country and 10 randomly selected households in each of these. One to two persons per selected household were interviewed to collect information on socio-demographics, symptoms suggestive of COVID-19, exposure history to laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. Capillary blood was collected by fingerstick, and blood samples were tested using the Hangzhou Biotest Biotech RightSign COVID-19 IgG/IgM Rapid Test Cassette. Total seroprevalence was was estimated after applying sampling weights.Findings The overall weighted seroprevalence was 2.6% (95% CI 1.9-3.4). This is 43 times higher than the reported number of cases. Rural seropositivity was 1.8% (95% CI 1.0-2.5), and urban seropositivity was 4.2% (95% CI 2.6-5.7).Interpretation Although overall seroprevalence was low compared to countries in Europe and the Americas (suggesting relatively successful containment in Sierra Leone), our findings indicate enormous underreporting of active cases. This has ramifications for the country’s third wave (which started in June 2021), where the average number of daily reported cases was 87 by the end of the month—this could potentially be on the order of 3,700 actual infections, calling for stronger containment measures in a country with only 0.2% of people fully vaccinated. It may also reflect significant underreporting of incidence and mortality across the continent.Funding This study was supported by NIAID K08 AI139361, the Sierra Leone Ministry of Health and Sanitation, and the Africa CDC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by NIAID K08 AI139361, the Sierra Leone Ministry of Health and Sanitation, and the Africa CDC. The funders of the study were not involved in reviewing the study design, writing of the manuscript, or the decision to submit the paper for publication. All authors had access to all the data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Sierra Leone Ethics and Scientific Review Committee. It received a Not Research Determination (IRB20-1394) from the Harvard Institutional Review Board as it was deemed Public Health Surveillance.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA subset of the key anonymized individual participant data collected is available upon request to the corresponding author, after approval of a proposal with a signed data access agreement.